ClouDr Group (9955) H1 2026 earnings summary

Executive summary

• H1 revenue fell 29.5% YoY to RMB629.2m amid VBP pressure and the phase-out of low-margin businesses; gross margin rose to 46.7% from 37.1%.

• Operating loss narrowed to RMB19.6m from RMB588.0m, and loss for the period narrowed 94.3% to RMB37.0m; adjusted net loss fell 86.0% to RMB8.9m.

• Strategy focuses on AI-enabled platforms, profitable P2M growth and cash generation, with data-asset monetization targeted over the medium to long term.

Financial highlights

• Revenue was RMB629.2m, down 29.5% YoY; gross profit was RMB293.7m, down 11.3%.

• Operating loss narrowed 96.7% to RMB19.6m; loss for the period narrowed 94.3% to RMB37.0m, and loss per share improved to RMB0.05 from RMB0.92.

• Adjusted net loss narrowed 86.0% to RMB8.9m from RMB63.4m; adjusted net loss margin was 1.4% versus 7.1%.

• Cost of sales declined 40.3% to RMB335.5m as low-margin value-added services made up a smaller share of sales.

• Net cash generated from operating activities was RMB20.2m; cash and cash equivalents were RMB240.5m at June 30, 2026.

Outlook and guidance

• Near-term priorities include P2M monetization, healthy cash flow and profitability; medium- to long-term plans target data-asset monetization and connecting healthcare stakeholders.

• Plans include expanding AI hospital and pharmacy platforms, proprietary product pipelines, medical AI, patient and doctor users, and pharmaceutical partnerships.

• Iloprost commercialization is expected to advance through the Greater Bay Area MDA network, alongside real-world research and NMPA CDE submission work.

• Out-of-hospital plans include expanding pharmacy installations and product and service offerings, with P2M intended to improve business-line profitability.